文献速递类风湿关节炎

不同JAK抑制剂对风湿病JAK亚型选择性的体外分析差异

Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
PubMed 文献 · Arthritis Rheumatol · 2023-08-03

该体外研究平行分析了10种JAK抑制剂对JAK亚型及细胞因子的选择性,发现抑制JAK激酶活性并不直接转化为细胞JAK/STAT信号抑制,已上市JAK抑制剂细胞因子抑制谱高度相似且偏好JAK1介导的细胞因子,新型JAK抑制剂则分别高选择性抑制JAK3或TYK2信号。

要点

  • 泛JAK抑制剂有效抑制2至3种JAK家族成员的激酶活性,亚型靶向JAK抑制剂对1至2种成员有不同程度选择性。
  • 已上市JAK抑制剂虽JAK选择性不同,但细胞因子抑制谱高度相似,均偏好抑制JAK1介导的细胞因子。
  • 利特昔替尼对JAK3的选择性为其他JAK的900至2500倍,氘可来昔替尼高特异性抑制IFNα信号且不影响JAK体外激酶活性。

核心结论

  • 抑制JAK激酶活性并不直接转化为对细胞JAK/STAT信号的抑制。
  • 已上市JAK抑制剂尽管JAK选择性存在差异,但细胞因子抑制谱高度相似,偏好JAK1介导的细胞因子。
  • 新型JAK抑制剂表现出针对JAK3或TYK2介导信号的窄谱细胞因子抑制谱。

研究设计与样本

  • 体外平行分析10种JAK抑制剂对JAK亚型的选择性,检测激酶活性抑制、与激酶及假激酶结构域结合以及对细胞因子信号的抑制。
  • 使用健康志愿者的血液样本以及类风湿关节炎患者和健康供者的外周血单个核细胞(PBMC)。

主要发现

  • 泛JAK抑制剂有效抑制2至3种JAK家族成员的激酶活性,亚型靶向JAK抑制剂对1至2种JAK家族成员具有不同程度的选择性。
  • 在人白细胞中,JAK抑制剂主要抑制JAK1依赖性细胞因子白细胞介素-2(IL-2)、IL-6和干扰素(IFN)。
  • 与健康对照相比,类风湿关节炎患者PBMC中这些细胞因子的抑制更为明显,并观察到一些细胞类型和STAT亚型差异。
  • 共价JAK抑制剂利特昔替尼对JAK3的选择性为其他JAK的900至2500倍,并特异性抑制IL-2信号。
  • 变构TYK2抑制剂氘可来昔替尼高特异性抑制IFNα信号,靶向调节性假激酶结构域,且不影响JAK体外激酶活性。

关键数值与推荐

  • 利特昔替尼对JAK3的选择性为其他JAK的900至2500倍。
  • 氘可来昔替尼高特异性抑制IFNα信号,且不影响JAK体外激酶活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The selectivity of JAK inhibitors (Jakinibs) forms the basis for understanding their clinical characteristics; however, evaluation of selectivity is hampered by the lack of comprehensive head-to-head studies. Our objective was to profile in parallel Jakinibs indicated or evaluated for rheumatic diseases for their JAK and cytokine selectivity in vitro. METHODS: We analyzed 10 Jakinibs for JAK isoform selectivity by assaying their inhibition of JAK kinase activity, binding to kinase and pseudokinase domains, and inhibition of cytokine signaling using blood samples from healthy volunteers and using isolated peripheral blood mononuclear cells (PBMCs) from patients with rheumatoid arthritis and from healthy donors. RESULTS: Pan-Jakinibs effectively suppressed kinase activity of 2 to 3 JAK family members, whereas isoform-targeted Jakinibs possessed varying degrees of selectivity for 1 or 2 JAK family members. In human leukocytes, Jakinibs predominantly inhibited the JAK1-dependent cytokines interleukin-2 (IL-2), IL-6, and interferons (IFNs). In PBMCs from patients with rheumatoid arthritis compared with healthy controls, inhibition of these cytokines was more pronounced, and some cell-type and STAT isoform differences were observed. Novel Jakinibs demonstrated high selectivity: the covalent Jakinib ritlecitinib showed 900- to 2,500-fold selectivity for JAK3 over other JAKs and specific suppression of IL-2-signaling, whereas the allosteric TYK2 inhibitor deucravacitinib inhibited IFNα signaling with high specificity. Interestingly, deucravacitinib targeted the regulatory pseudokinase domain and did not affect JAK in vitro kinase activity. CONCLUSION: Inhibition of JAK kinase activity did not directly translate into cellular inhibition of JAK/STAT signaling. Despite differences in JAK selectivity, the cytokine inhibition profiles of currently approved Jakinibs were highly similar, with preference for JAK1-mediated cytokines. Novel types of Jakinibs showed narrow cytokine inhibition profile specific for JAK3- or TYK2-mediated signaling.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Virtanen A, Palmroth M, Liukkonen S, et al. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling. Arthritis Rheumatol. 2023. PMID: 37134144. doi:10.1002/art.42547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。